Verrica Pharmaceuticals VRCA 深 滬
已收盤 09-19 16:00:00 美东时间
4.39
+0.350
+8.66%
華盛通- 最 高4.90
- 今 開4.48
- 成交量 812.11万股
- 最 低 4.13
- 昨 收 4.04
- 總市值 4146.71万
- 52周最高 17.382
- 市盈率 靜 --
- 換手率 85.98%
- 52周最低 3.816
- 委 比 89.47%
- 總股本 944.58万
- 歷史最高 232.90
- 量 比 98.04
- 振 幅 19.06%
- 歷史最低 3.816
- 每 手 1
- 風險率 2.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Verrica Pharmaceuticals shares are trading higher after development partner Torii Pharmaceutical received Japan approval for YCANTH to treat molluscum contagiosum, triggering a $10M payment to Verrica.
Verrica Pharmaceuticals shares are trading higher after development partner Tor...
09-19 20:04
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals announced that its partner, Torii Pharmaceutical Co. Ltd., has received approval from Japan's Ministry of Health for YCANTH® (TO-208) to treat molluscum contagiosum. This approval triggered a $10 million milestone payment to Verrica and addresses an unmet need for patients in Japan. Verrica retains global rights for YCANTH outside of Japan. The company plans to leverage this funding to support U.S. commercial activities an...
09-19 12:00
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Verrica Pharmaceuticals Inc.'s CEO, Jayson Rieger, will speak at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025, in New York City. The event includes a live webcast accessible via provided links. Verrica focuses on dermatology treatments, notably YCANTH® (VP-102) for molluscum contagiosum and common warts, and collaborates with Lytix Biopharma AS on VP-315 for non-melanoma skin cancers.
09-02 11:00
Verrica Pharmaceuticals Q2 Adj. EPS $0.25 Beats $(0.07) Estimate, Sales $12.702M Beat $4.367M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $(0.07) by 457.14 percent. This is a 180.65 percent increase over losses of $(0.31) per
08-13 04:02
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
What to Expect from Verrica Pharmaceuticals's Earnings
Verrica Pharmaceuticals (NASDAQ:VRCA) is preparing to release its quarterly ear...
08-12 04:03
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
Verrica Pharmaceuticals Inc. will host a conference call on August 12, 2025, at 4:30 p.m. ET to discuss its Q2 2025 financial results and provide a corporate update. Participants can join via phone using the conference ID: VERRICA or access the live webcast on www.verrica.com. A replay will be available for 90 days. Verrica develops dermatology treatments, including YCANTH® for molluscum contagiosum and common warts, and VP-315 for non-melanoma s...
08-06 11:00
Verrica Reports Record 13,434 YCANTH Applicator Units Dispensed In Q2 2025, Marking 32.8% Sequential Growth
– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH Dispensed applicator units in Q2 2025 –– Company reports receipt of $8 million milestone payment from its Japanese
07-09 19:05
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
Verrica Pharmaceuticals Inc. reported a 32.8% sequential quarterly growth in Q2 2025, with 13,434 YCANTH® dispensed applicator units sold. The company also received an $8 million milestone payment from its Japanese partner, Torii Pharmaceutical, for initiating a global Phase 3 program for common warts. YCANTH, approved by the FDA for treating molluscum contagiosum, shows strong demand driven by a focused commercial strategy, improved patient acce...
07-09 11:00
Verrica Pharmaceuticals Announces Second Amendment To Its Existing Collaboration And Licensing Agreement With Torii Pharmaceutical To Initiate A Global Pivotal Phase 3 Trial Of Verrica's Ycanth For Common Warts
Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule.Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of
07-01 19:06
